Showing 5511-5520 of 6808 results for "".
- Amytrx Therapeutics Comes Out of the Gate Strong with Lead Program AMTX-100, Clinical Development Planshttps://practicaldermatology.com/news/amytrx-therapeutics-comes-out-of-the-gate-strong-with-lead-program-amtx-100-clinical-development-plans/2460531/Amytrx Therapeutics, Inc. is on the move. Founded in 2014, Nashville-based Amytrx is developing novel therapies for inflammatory diseases with lead program AMTX-100 currently in clinical development for dermatologic indications. AMTX-100 is a new anti-inflammatory therape
- Drumroll, Please...Gwyneth Paltrow Named Global Face of Xeominhttps://practicaldermatology.com/news/gwyneth-paltrow-named-global-face-of-xeomin/2460530/Actress and Goop wellness guru Gwyneth Paltrow is the first global face of Merz Aesthetics' Xeomin. In this role, Paltrow will be sharing details about what she does to look and feel her best, and will ask women to do the same on social media using #DareToSelfCare. “
- Lilly Launches Digital Health Open Innovation Challenge to Help Transform AD Carehttps://practicaldermatology.com/news/lilly-launches-digital-health-open-innovation-challenge-to-help-transform-ad-care/2460529/Eli Lilly and Company is launching an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions to help make life better for people living with atopic dermatitis. The challenge, "Transforming Atopic Der
- Arcutis to Accelerate Program for ARQ-151 for Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-to-accelerate-program-for-arq-151-for-atopic-dermatitis/2460520/Arcutis Biotherapeutics, Inc. plans to advance its program to develop ARQ-151 (topical roflumilast cream) for the treatment of atopic dermatitis into Phase 3 clinical trials without conducting the previously planned Phase 2b atopic dermatitis trial. The decision follows an End
- Keystone Dermatology Virtual CME Conference Coming October 8-10https://practicaldermatology.com/news/keystone-dermatology-virtual-cme-conference-coming-october-8-10/2460517/Pennsylvania Dermatology Physician Assistants has transitioned its annual meeting to a virtual format. Registration is now open for Keystone Dermatology Virtual CME Conference, to be held October 8-10, 2020. Early bird registration ends September 8. Topics to be
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in
- Cyndi Lauper to Host New Novartis PsO Podcasthttps://practicaldermatology.com/news/cyndi-lauper-to-host-new-novartis-pso-podcast/2460514/Novartis is launching PsO in the Know, a podcast series hosted by music icon Cyndi Lauper. PsO in the Know will feature a variety of guests, including Chef Aarón Sánchez, actress and New York Times best-selling author La La Anthony, and Emmy
- Revance Commercial Infrastructure to Launch RHA Collection of Dermal Fillershttps://practicaldermatology.com/news/revance-commercial-infrastructure-to-launch-rha-collection-of-dermal-fillers/2460512/Revance Therapeutics, Inc. will begin introducing the RHA Collection of dermal fillers, Resilient Hyaluronic Acid, and the HintMD financial technology platform, in the United States in September. The RHA Collection of derma
- Positive Phase 3 Results for Dermavant's Tapinarof Cream for Plaque Psoriasishttps://practicaldermatology.com/news/positive-phase-3-results-results-for-dermavants-tapinarof-cream-for-plaque-psoriasis/2460511/Dermavant Sciences shared positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream 1% in adult patients with plaque psoriasis. In both PSOARING 1 (N
- MC2 Partners with EPI for Commercialization of Wynzorahttps://practicaldermatology.com/news/mc2-partners-partners-with-epi-for-commercialization-of-wynzora/2460510/MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US. Wynzora Cream was approvedby the FDA last month for the topical treatment of plaque psoriasis in adult